MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced upcoming presentations by the Company and a collaborator at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 24 – 27, 2023 in Chicago, Ill. Presentations on investigational clinical and preclinical studies of therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology are being made at the conference. They include early clinical experience and a preclinical evaluation of 177Lu-rhPSMA-10.1, currently being investigated by Blue Earth Therapeutics as a potential PSMA-targeted therapeutic radiopharmaceutical candidate for the treatment of prostate cancer.
NOTE: Currently, therapeutic radiohybrid (rh) PSMA compounds are investigational and have not received regulatory approval. Presentations noted by “*” discuss results that are investigational and are not approved by the FDA.
Investigational 177Lu-rhPSMA-10.1
Poster presentations
NOTE: Poster presentations are available Saturday, June 24, 2023, from 6:00 – 8:00 PM CT and throughout the meeting in the Science Pavilion. Times for Meet the Author sessions are below.
| Monday, June 26, 2023 | ||
|
||
Title: |
*Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T – an intrapatient comparison |
|
Presenter: |
Ralph Bundschuh, MD, PhD, Nuclear Medicine, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany |
|
Session Title: |
MTA04-A12 Meet the Author: Oncology: Clinical Therapy & Diagnosis – Group A |
|
Session Time: |
11:15 – 11:45 AM CT |
|
Area: |
Science Pavilion Pod 12: Oncology Clinical Therapy & Diagnosis |
|
Program ID: |
346 |
|
|
||
|
||
| Tuesday, June 27, 2023 | ||
|
||
Title: |
*Enhanced therapeutic response to 177Lu-rhPSMA-10.1 in pre-clinical models of prostate cancer |
|
Presenter: |
Caroline Foxton, Ph.D., Blue Earth Therapeutics, Oxford, UK |
|
Session Title: |
MTA 06-B10 Meet the Author: Neurosciences/Oncology Basic & Translational – Group B |
|
Area: |
Science Pavilion Pod 10: Oncology Basic and Translational |
|
Session Time: |
1:00 – 1:30 PM CT |
|
Program ID: |
621 |
|
Blue Earth Therapeutics invites participants at the 2023 SNMMI Annual Meeting to learn more about its clinical program in the Medical Affairs information booth of its sister company, Blue Earth Diagnostics, at Booth 6025. For full session details and scientific presentation lists, please see the SNMMI online program here. Information about Blue Earth Diagnostics presence at SNMMI is available here.
About Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA)
Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) compounds consist of a radiohybrid (“rh”) Prostate-Specific Membrane Antigen-targeted receptor ligand which attaches to and is internalized by prostate cancer cells, and they may be radiolabeled with imaging isotopes for PET imaging, or with therapeutic isotopes for therapeutic use – providing the potential for creating a true theranostic technology. Radiohybrid technology and rhPSMA originated from the Technical University of Munich, Germany. Blue Earth Diagnostics acquired exclusive, worldwide rights to rhPSMA diagnostic imaging technology from Scintomics GmbH in 2018, and therapeutic rights in 2020, and sublicensed the therapeutic application to its sister company Blue Earth Therapeutics. Blue Earth Diagnostics received U.S. Food and Drug Administration approval for its radiohybrid PET diagnostic imaging product for use in prostate cancer in 2023. rhPSMA compounds for potential therapeutic use are investigational and have not received regulatory approval.
About Blue Earth Therapeutics
Blue Earth Therapeutics, one of the Bracco family of companies, is a clinical stage company dedicated to advancing next generation targeted radiotherapeutics to treat patients who have cancer. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start-up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases. Blue Earth Therapeutics has an emerging pipeline, initially focused on prostate cancer, and with plans to expand into additional disease areas in oncology. Blue Earth Therapeutics is an indirect subsidiary of Bracco Imaging S.p.A, and based in Oxford, UK. For more information, please visit: www.blueearththerapeutics.com.
About Bracco Imaging
Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies. Visit: www.braccoimaging.com.
